WS
PDLI

Wedbush Securities’s PDL BioPharma, Inc. PDLI Stock Holding History

Wedbush Securities’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,000
Closed -$23K – 906
2017
Q1 		$23K Sell
10,000
-1,500
-13% -$3.32K ﹤0.01% 827
2016
Q4 		$24K Buy
+11,500
New +$32.1K ﹤0.01% 802
2014
Q4 		– Sell
-10,500
Closed -$78K – 793
2014
Q3 		$78K Buy
+10,500
New +$97.5K 0.01% 642

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Wedbush Securities's PDLI Position: Q2 2017 in Review

Wedbush Securities sold out of PDL BioPharma, Inc. (PDLI) in Q2 2017, closing a stake of 10,000 shares — an estimated $23K sold.

Wedbush Securities first reported a position in PDLI in Q3 2014 and held it in 3 quarters. The position peaked at $78K in Q3 2014. 171 funds tracked by Wall St. Rank hold PDLI as of Q2 2017.

  • Wedbush Securities reported no remaining PDL BioPharma, Inc. position as of Q2 2017 after selling out during the quarter.
  • Wedbush Securities sold 10,000 PDL BioPharma, Inc. shares in Q2 2017, an estimated $23K.
  • Wedbush Securities first reported a position in PDL BioPharma, Inc. in Q3 2014 and held it in 3 quarters.
  • Wedbush Securities's PDL BioPharma, Inc. position peaked at $78K in Q3 2014.
  • 171 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2017.

Based on Wedbush Securities's 13F filing for Q2 2017, filed 2 Aug 2017.